Trial Profile
CHEMOIMMUNE - A Phase II Study Evaluating an Anti-PD1 Monoclonal Antibody (Pembrolizumab) in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Cyclophosphamide
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms CHEMOIMMUNE
- 26 Aug 2020 Status changed from active, no longer recruiting to completed.
- 14 Jun 2019 Status changed from recruiting to active, no longer recruiting.
- 27 Jun 2017 Status changed from not yet recruiting to recruiting.